Jan Verwerft
Overview
Explore the profile of Jan Verwerft including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
78
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Bekhuis Y, Verwerft J, Claessen G
J Am Coll Cardiol
. 2024 Apr;
83(14):e141-e142.
PMID: 38569769
No abstract available.
12.
Hoedemakers S, Pugliese N, Stassen J, Vanoppen A, Claessens J, Gojevic T, et al.
Circulation
. 2024 Feb;
149(15):1172-1182.
PMID: 38410954
Background: Recent guidelines redefined exercise pulmonary hypertension as a mean pulmonary artery pressure/cardiac output (mPAP/CO) slope >3 mm Hg·L·min. A peak systolic pulmonary artery pressure >60 mm Hg during exercise...
13.
Dhont S, Stassen J, Herbots L, Hoedemakers S, Bekhuis Y, Jasaityte R, et al.
Eur Heart J Cardiovasc Imaging
. 2023 Nov;
25(4):530-538.
PMID: 37976175
Aims: Exercise-induced pulmonary hypertension (PH), defined by a mean pulmonary arterial pressure over cardiac output (mPAP/CO) slope >3 mmHg/L/min, has important diagnostic and prognostic implications. The aim of this study...
14.
Hoedemakers S, Verwerft J, Reddy Y, Delvaux R, Stroobants S, Jogani S, et al.
Eur Heart J Cardiovasc Imaging
. 2023 Oct;
25(3):302-312.
PMID: 37875135
Aims: To study the impact of heart failure with preserved ejection fraction (HFpEF) vs. aortic stenosis (AS) lesion severity on left ventricular (LV) hypertrophy, diastolic dysfunction, left atrial (LA) dysfunction,...
15.
Verbeeck J, De Backer M, Verwerft J, Salvaggio S, Valgimigli M, Vranckx P, et al.
J Am Coll Cardiol
. 2023 Sep;
82(13):1360-1372.
PMID: 37730293
A time-to-first-event composite endpoint analysis has well-known shortcomings in evaluating a treatment effect in cardiovascular clinical trials. It does not fully describe the clinical benefit of therapy because the severity...
16.
Mewis S, Brammerloo A, Verwerft J
Eur Heart J Acute Cardiovasc Care
. 2023 Aug;
12(9):646-647.
PMID: 37652893
No abstract available.
17.
Mewis S, Brammerloo A, Verwerft J
Eur Heart J Acute Cardiovasc Care
. 2023 Aug;
12(9):644-645.
PMID: 37621065
No abstract available.
18.
Verwerft J, Soens L, Wynants J, Meysman M, Jogani S, Plein D, et al.
Eur Heart J
. 2023 Mar;
44(17):1544-1556.
PMID: 36924194
Background And Aims: Heart failure with preserved ejection fraction (HFpEF) is a syndrome with a heterogeneous presentation. This study provides an in-;depth description of haemodynamic and metabolic alterations revealed by...
19.
Stassen J, Falter M, Herbots L, Timmermans P, Dendale P, Verwerft J
JACC Cardiovasc Imaging
. 2023 Mar;
16(3):426-431.
PMID: 36889855
No abstract available.
20.
Verwerft J, Bertrand P, Claessen G, Herbots L, Verbrugge F
JACC Heart Fail
. 2023 Feb;
11(2):243-249.
PMID: 36754531
No abstract available.